Phaseline

Targets › KAPPA

KAPPA: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jul 2035.

Open in Phaseline: the race on KAPPA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Baylor College of MedicineKappa CD28 T cells
Genetically engineered T cells expressing kappa-restricted TCR with CD28 costimulation dom
KAPPAPhase 1LymphomaJul 2035

Conditions

Lymphoma (1)

Modalities

other (1)

Companies

Baylor College of Medicine (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.